# Very low monomethyl fumarate exposure via human milk: a case report—a contribution from the ConcePTION project

**Authors:** Martje Van Neste, Nina Nauwelaerts, Michael Ceulemans, Benedikte Cuppers, Pieter Annaert, Anne Smits, Karel Allegaert

PMC · DOI: 10.3389/fpubh.2024.1393752 · Frontiers in Public Health · 2024-07-02

## TL;DR

This case report examines how much of a drug's active ingredient passes into breast milk and reaches an infant, finding very low exposure.

## Contribution

The study provides new pharmacokinetic data on monomethyl fumarate transfer to human milk at 3 months postpartum.

## Key findings

- MMF concentrations in human milk ranged from 5.5 to 83.5 ng/mL.
- Estimated infant doses were 5.76 and 7.68 μg/kg/day, with relative doses of 0.16 and 0.22%.
- The milk-to-plasma ratio was 0.059, consistent with model predictions.

## Abstract

While breastfeeding is recommended, knowledge regarding medicine transfer to human milk and its safety for nursing infants is limited. Only one paper has previously described dimethyl fumarate (DMF) transfer during breastfeeding in two patients at 5 and 6 months postpartum, respectively. The current case report describes maternal pharmacokinetic data of monomethyl fumarate (MMF), the active metabolite of DMF, and infant exposure estimations of MMF at 3 months postpartum.

A 32-year-old Caucasian woman started DMF therapy (120 mg, 2x/day) for multiple sclerosis at 3 months postpartum, after weaning her infant from breastfeeding. On day 99 after birth, the patient collected four milk samples over 24 h after 6 days of treatment at the initial dose. Additionally, a single maternal blood sample was collected to calculate the milk-to-plasma (M/P) ratio. The samples were analyzed using liquid chromatography coupled with the mass spectrometry method.

A wide range of measured steady-state concentrations of MMF (5.5-83.5 ng/mL) was observed in human milk samples. Estimated daily infant dosage values for MMF, calculated with 150 and 200 mL/kg/day human milk intake, were 5.76 and 7.68 μg/kg/day, and the relative infant doses were 0.16 and 0.22%. The observed mean M/P ratio was 0.059, similar to the M/P ratio predicted using the empirical Koshimichi model (0.06).

Combining this case report with the two previously described cases, the estimated infant exposure is low, albeit with relevant intra- and inter-patient variabilities. Research should further focus on infant exposure and safety.

## Linked entities

- **Chemicals:** monomethyl fumarate (PubChem CID 5369209), dimethyl fumarate (PubChem CID 637568)
- **Diseases:** multiple sclerosis (MONDO:0005301)

## Full-text entities

- **Diseases:** multiple sclerosis (MESH:D009103)
- **Chemicals:** MMF (MESH:C509058), DMF (MESH:D000069462)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11250615/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11250615/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC11250615/full.md

---
Source: https://tomesphere.com/paper/PMC11250615